Harold Neuhof, MD, is appointed Director of Neurosurgical Service at The Mount Sinai Hospital.

The Neurosurgery Service becomes a separate department, and Ira Cohen, MD, is named the Department’s first Director. 

Ira S. Cohen, MD, established the first formal neurosurgery residency program at Mount Sinai.

Aron J. Beller, MD, becomes Mount Sinai’s first neurosurgery resident. He later becomes Chair of the Department of Neurosurgery at the Hadassah Hospital in Jerusalem.

Leo Davidoff, MD, is appointed Director of the Department of Neurosurgery at The Mount Sinai Hospital.

Sidney Gross, MD, is named Director of the Department of Neurosurgery at The Mount Sinai Hospital.

Leonard I. Malis, MD, performs the first microneurosurgical operation at The Mount Sinai Hospital.

Leonard I. Malis, MD, becomes Chair of the Department of Neurosurgery at The Mount Sinai Hospital.

Alejandro Berenstein, MD, and Harold A. Mitty, MD, perform the world’s first catheter-based therapeutic embolization for a GI bleeder following a gastrectomy. 

The Mount Sinai Medical Center Neurosciences Intensive Care Unit (NSICU) is founded.

Kalmon D. Post, MD, becomes Chair of the Department of Neurosurgery at Mount Sinai Medical Center. During his tenure, Dr. Post significantly expanded the Department, in personnel, areas of clinical academic and research expertise, resources, and physical space.

Joshua B. Bederson, MD, joins the Department of Neurosurgery, becoming the first cerebrovascular neurosurgeon at Mount Sinai Medical Center and establishing the cerebrovascular neurosurgical program.

Isabelle M. Germano, MD, MBA, performs the first-in-human intra-operative use of the optical digitizer for neuro-navigation in the United States.

Isabelle M. Germano, MD, MBA, is the first neurosurgeon in the United States to implant bilateral deep brain stimulation of the subthalamic nucleus.

Isabelle M. Germano, MD, MBA, is Principal Investigator of the first-in-human New York State clinical trial using adenoviral gene therapy for recurrent glioblastoma.

Isabelle M. Germano, MD, MBA, performs the first GPi Deep Brain Stimulation for dystonia in the United States.

Isabelle M. Germano, MD, MBA, and Kalmon D. Post, MD, perform the first intra-operative use of the optical digitizer for neuro-navigation in the United States.

Isabelle M. Germano, MD, MBA, performs the first gene delivery in the mouse brain by embryonic stem cell derived astrocytes in the United States.

Joshua B. Bederson, MD, becomes Chair of the Department of Neurosurgery at Mount Sinai Medical Center.

Brian H. Kopell, MD, establishes Mount Sinai’s Center for Neuromodulation, the first tri-state area comprehensive neuromodulation center.

The Department of Neurosurgery becomes the largest program in New York City after Mount Sinai merges with Continuum Health Partners.

Raj K. Shrivastava, MD, and Priti Balchandani, PhD, are the first team in the world to develop and begin clinical trials for the application and use of High Field 7T MRI imaging in the planning and operative guidance in complex endoscopic skull base surgery.

Johanna T. Fifi, MD, becomes the first woman physician and first neurologist in the United States to use the Woven EndoBridge Aneurysm Embolization System to treat an aneurysm.

J Mocco, MD, MS, completes the world’s first prospective randomized trial demonstrating the value of aspiration thrombectomy in treating patients suffering acute stroke from larger vessel occlusion.

Saadi Ghatan, MD, is the first neurosurgeon to implant a NeuroPace responsive neurostimulator for uncontrolled epilepsy in a child.

Brian H. Kopell, MD, performs the first iMRI deep brain stimulation case in New York City.

Eric K. Oermann, MD, is the first Verily (formerly Google Life Sciences) Clinical Fellow and developed revolutionary projects in machine learning and surgery.

Thomas J. Oxley, MD, PhD, is published in Nature Biotechnology for his study on his brain-computer interface device called the Stentrode.

Joshua B. Bederson, MD, becomes the first neurosurgeon to use CaptiView—a microscope image injection system from Leica Microsystems that overlays critical augmented reality imaging directly onto the brain when viewed through the eyepiece, known as the ocular, during surgery. 

Mount Sinai is the first hospital in New York City to perform approved fluorescence-guided surgery for malignant gliomas with the use of an orphan drug known as Gliolan®.

Neha S. Dangayach, MD, MSCR, establishes the Neuroemergencies Management and Transfers (NEMAT) Program.

Brian H. Kopell, MD, is the first neurosurgeon in the United States to implant St. Jude Medical’s Infinity™ deep brain simulation system, designed to deliver enhanced patient comfort, including proprietary directional lead technology, which helps steer current toward areas that may help maximize patient outcomes and reduce side effects, as well as programming with a wireless iOS software mobile platform.

J Mocco, MD, MS, performs the first thrombectomy in the borough of Queens, at Mount Sinai Queens.

Christopher P. Kellner, MD, establishes a program dedicated to directing all intracerebral hemorrhage patients to one dedicated hospital for treatment and research, the first of its kind in the world.

With a publication in Nature Medicine, Mount Sinai is the first hospital to study artificial intelligence for detecting acute neurologic events and demonstrating its direct clinical application.

Joshua B. Bederson, MD, and Anthony B. Costa, PhD, establish Mount Sinai BioDesign.

Helen S. Mayberg, MD, establishes the Nash Family Center for Advanced Circuit Therapeutics.

Joshua B. Bederson, MD, and Mount Sinai are one of the first in the country to use the ZEISS KINEVO® 900 microscope, a surgeon-driven, robotic visualization system that merges the functionality of a surgical microscope with 4K resolution and 3D visualization along with specialized robotic control.

The Cerebrovascular Stroke Center is established at Mount Sinai Queens, the world's first state-of-the-art, thrombectomy-capable stroke treatment center custom designed to provide the fastest and most efficient treatment of large vessel occlusion stroke.

Neha Dangayach, MD, MSCR, and Joshua B. Bederson, MD, establish a state-of-the-art Neurosciences Intensive Care Unit at The Mount Sinai Hospital.

Mount Sinai Neurosurgery ranks No. 1 in New York State in the Blue Ridge Institute for Medical Research rankings in National Institutions of Health funding, with more than $1.9 million in funding committed to research.

The NoMo valve becomes the first technology incubated by Mount Sinai BioDesign to get licensed to an outside medtech company, creating a new product category for cerebrovascular-focused hemostatic valves.

Brian H. Kopell, MD, is the first in New York to implant Medtronic's SenSight™ Directional Lead System with brain sensing capability for a Parkinson's patient.

Mount Sinai Health System Neuroemergencies Management and Transfers lab launched with a mission to leverage technology and innovations throughout the continuum of care from triage to recovery for all neuroemergencies.

Brian H. Kopell, MD, is the first in the world to perform in vivo recording of dopamine and serotonin in subgenual anterior cingulate cortex in a human.

Benjamin I. Rapoport, MD, PhD, becomes the Scientific Director of Mount Sinai BioDesign.

Jeremy M. Steinberger, MD, facilitates bringing the 7D OR technology to Mount Sinai Health System, with Mount Sinai being the first health system in the United States to arrange the device across multiple hospitals in its health system.

Fedor E. Panov, MD, performs the first vagus nerve stimulation surgery for stroke rehabilitation at Mount Sinai West, one of the first cases in the United States. The Enhanced Stroke Recovery Program was also founded by Christopher P. Kellner, MD.

The Neurosurgery Residency Program matches with two females in the same residency year for the first time.

Mount Sinai BioDesign is awarded $11.6 million from the New York City Economic Development Corporation’s Life Science Innovation Infrastructure Fund to support the development of the Comprehensive Center for Surgical Innovation, a first-of-its kind center in the New York metro area for the development, production, and testing of novel medical device technologies

Mount Sinai Neurosurgery ranks No. 20 in the Nation and No. 1 in New York State in the Blue Ridge Institute for Medical Research rankings in National Institutions of Health funding, with more than $2.6 million in funding committed to research.

Isabelle M. Germano, MD, MBA, is elected Chair of the American Association of Neurological Surgeons/Congress of Neurological Surgeons Section on Tumors, the largest organization of brain and spine tumor neurosurgeons world-wide. She becomes the first woman to lead this organization.

Isabelle M. Germano, MD, MBA, publishes Neurosurgery and Global Health (Springer Nature), marking the worldwide initial book publication on this topic.

Isabelle M. Germano, MD, MBA, becomes Program Director of the United Council for Neurologic Subspecialties Neuro-Oncology Fellowship, Department of Neurology, and matches the inaugural fellow.

Shahram Majidi, MD, is the first in the United States to perform the first endovascular human brain-computer interface—the Stentrode—invented by Thomas J. Oxley, MD, PhD.

Isabelle Germano, MD, MBA is awarded the first Congress of Neurological Surgeons International Observership for Tumors to take place at Mount Sinai.

A team of Mount Sinai surgeons, led by neurosurgeon Jeremy M. Steinberger, MD, presents the first reported case of a fully robotic anterior and posterior (circumferential) spinal fusion surgery.

The Mount Sinai Health System Patient Recovery and Caregiver Interventions for Stroke Excellence (PRECISE) program launches.

Joshua B. Bederson, MD, is the first neurosurgeon in New York State to utilize the Synaptive Modus X, a high-tech robotic exoscope, during brain surgery.

Viz.ai receives first de novo approval by the FDA for AI algorithm for hypertrophic cardiomyopathy, made possible through collaboration with Mount Sinai BioDesign.

In the scientific journal Nature, Helen S. Mayberg, MD, the co-senior author of the study, pioneered the examination of brain activity in individuals undergoing deep brain stimulation. The research team successfully pinpointed a distinctive pattern of brain activity indicative of the recovery process in patients grappling with treatment-resistant depression.

Mount Sinai is the first in New York to study a new brain-computer interface, Layer 7 Cortical Interface, developed by Precision Neuroscience Corporation, that is engineered to map a large area of the brain’s surface, in real time, at resolutions hundreds of times more detailed than typical arrays used in neurosurgical procedures.

Mount Sinai Health System and Precision Neuroscience Corporation achieved the world record for the number of electrodes placed on and recording cortical data from a human brain, a total of 4,096 electrodes.